Last reviewed · How we verify
S.sonnei vaccine
At a glance
| Generic name | S.sonnei vaccine |
|---|---|
| Also known as | GSK3536852A vaccine |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old (PHASE2)
- A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults (PHASE2)
- Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate (PHASE1, PHASE2)
- Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S.sonnei vaccine CI brief — competitive landscape report
- S.sonnei vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI